Novartis sees EU, Swiss drop antitrust probes into 'blocking patent'
Novartis's move to acquire patents for a psoriasis drug from Genentech and then enforce them against rival drugmaker Eli Lilly have escaped antitrust prosecution after regulators in the EU and Switzerland...To view the full article, register now.
Already a subscriber? Click here to view full article